AMGN continues its quiet grind higher — up another 1.7% on the week to close at $368.10 — yet the analyst community used the move to trim targets rather than lift conviction, leaving the stock in an uncomfortable position: trading above most Street price targets with Q2 results less than four weeks away.
The lending market tells a story of almost zero bearish pressure. Availability remains extraordinarily loose at roughly 5,036% — around 50 shares available to lend for every one currently borrowed — down from the prior week's ~5,500% but still a level that implies no meaningful institutional appetite to build short positions. Short interest has nudged 4% higher on the week to 2.4% of the free float, reversing a brief dip but staying well below the June 8 peak. Borrowing cost is negligible at 0.48% annualised, and has actually fallen 8% on the week. Options positioning, meanwhile, remains mildly constructive: the put/call ratio is running at 0.76, more than one standard deviation below its 20-day average of 0.81, continuing the shift toward call activity that appeared in the prior week. The borrow and options data together describe a market that is not bracing for a fall.
The analyst picture is more complicated. Three separate actions hit the tape in the past 48 hours — and none of them were bullish. Morgan Stanley's Terence Flynn cut his target to $333 from $340 while holding an Equal-Weight rating, meaning AMGN is now trading almost $35 above that target. Truist raised its target to $340 from $327, a constructive move, but kept a Hold. Cantor Fitzgerald reiterated Neutral with a $350 target. The pattern across the broader recent-changes list is similar: most firms are clustered in Hold/Neutral/Equal-Weight territory, with the notable exception of Piper Sandler's Overweight and UBS's Buy. The consensus price target averages around $355, now running roughly 3.5% below where the stock trades — an unusual inversion that typically signals the Street is waiting for data rather than willing to chase price. Bears point to patent expiration risk on core drugs, pricing pressure in the biopharma channel, and early-stage uncertainty around pipeline expansion. Bulls anchor to the diversified biologics portfolio and Tezspire's continued growth trajectory.
Institutional ownership offers a stabilising backdrop. BlackRock holds 8.7% of shares and added roughly one million shares in the most recent reported period. Capital Research added over three million shares to reach 8.1%. JP Morgan Asset Management added 3.7 million shares — the largest absolute addition in the top-holder list. These are largely passive or semi-passive flows, but the direction is additive. Insider activity tells a different story: on May 7, virtually every senior officer — CFO Peter Griffith, CTO David Reese, Chief Scientific Officer James Bradner, and several Executive Vice Presidents — sold shares on the same day at $331. The sales were small individually and may reflect routine plan-driven activity, but the breadth of the cluster is worth noting.
Among the closest correlated peers, GILD outpaced the group with a 7.9% weekly gain and ALNY added 9.6%. REGN rose 7.0%. By comparison, AMGN's 1.7% gain looks restrained — which may simply reflect its larger market capitalisation and different near-term catalyst exposure, or may reflect the target-inversion dynamic weighing on relative sentiment.
The August 4 earnings date is the clearest focal point from here. The last two quarterly prints produced modest moves in both directions — a 2.2% gain after the May report and a 2.4% decline after the April report — suggesting the stock is not pricing in a dramatic swing either way. With the stock now above consensus targets and the Street uniformly non-committal, the Q2 print's guidance commentary on Tezspire momentum and any update on biosimilar competition timelines will determine whether analysts have reason to reset their targets higher or lower.
See the live data behind this article on ORTEX.
Open AMGN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
